Evidence map›Paper›PMID 25752553›Full record

ArticleThe Lancet. Oncology2015

Japanese regulatory authority's perspective on biosimilars - authors' reply.

Charles L Bennett, Brian Chen, Terhi Hermanson, Peter Georgantopoulos, Oliver A Sartor

Abstract readLetterComment
PubMed Full text at PMC Publisher
In one paragraph

Article in The Lancet. Oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Charles L BennettSouth Carolina Center of Economic Excellence for Medication Safety and Efficacy and the Southern Network on Adverse Reactions (SONAR), South Carolina College of Pharmacy, the University of South Carolina, Columbia, USA; WJB Dorn VA Medical Center, Columbia, SC, USA; Hollings Cancer Center, Charleston, SC, USA; Arnold School of Public Health, University of South Carolina, Columbia, SC, USA. Electronic address: bennettc@sccp.sc.edu.
Brian ChenSouth Carolina Center of Economic Excellence for Medication Safety and Efficacy and the Southern Network on Adverse Reactions (SONAR), South Carolina College of Pharmacy, the University of South Carolina, Columbia, USA; Arnold School of Public Health, University of South Carolina, Columbia, SC, USA.
Terhi HermansonDepartment of Oncology, Helsinki University Central Hospital, Helsinki, Finland.
Peter GeorgantopoulosSouth Carolina Center of Economic Excellence for Medication Safety and Efficacy and the Southern Network on Adverse Reactions (SONAR), South Carolina College of Pharmacy, the University of South Carolina, Columbia, USA; WJB Dorn VA Medical Center, Columbia, SC, USA; Arnold School of Public Health, University of South Carolina, Columbia, SC, USA.
Oliver A SartorTulane Cancer Center, Tulane University School of Medicine, New Orleans, LA, USA.

Funding

Southern Oncology Network on Adverse Reactions (SONAR) - Focus on Tyrosine KinaseR01CA165609 · NCI · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI BENNETT, CHARLES L. · 2012 to 2016
$2.2M
NCI NIH HHS R01 CA165609
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antineoplastic AgentsBiosimilar PharmaceuticalsDrug ApprovalHumansNeoplasmsAntineoplastic AgentsBiosimilar Pharmaceuticals

Identifiers

PMID25752553
PMCPMC5105594

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.